252 related articles for article (PubMed ID: 7826527)
1. Tumor immunotherapy: the tumor cell as an antigen-presenting cell.
Ostrand-Rosenberg S
Curr Opin Immunol; 1994 Oct; 6(5):722-7. PubMed ID: 7826527
[TBL] [Abstract][Full Text] [Related]
2. Turning tumour cells into antigen presenting cells: The next step to improve cancer immunotherapy?
de Charette M; Marabelle A; Houot R
Eur J Cancer; 2016 Nov; 68():134-147. PubMed ID: 27755997
[TBL] [Abstract][Full Text] [Related]
3. MHC class II restricted tumor antigens and the role of CD4+ T cells in cancer immunotherapy.
Topalian SL
Curr Opin Immunol; 1994 Oct; 6(5):741-5. PubMed ID: 7826529
[TBL] [Abstract][Full Text] [Related]
4. Presentation of native TROP-2 tumor antigens to human cytotoxic T lymphocytes by engineered antigen-presenting cells.
Mangino G; Grazia Capri M; Barnaba V; Alberti S
Int J Cancer; 2002 Oct; 101(4):353-9. PubMed ID: 12209960
[TBL] [Abstract][Full Text] [Related]
5. Generation of cellular immune responses to antigenic tumor peptides.
Pietersz GA; Apostolopoulos V; McKenzie IF
Cell Mol Life Sci; 2000 Feb; 57(2):290-310. PubMed ID: 10766024
[TBL] [Abstract][Full Text] [Related]
6. Human antigen-presenting cell/tumour cell hybrids stimulate strong allogeneic responses and present tumour-associated antigens to cytotoxic T cells in vitro.
Dunnion DJ; Cywinski AL; Tucker VC; Murray AK; Rickinson AB; Coulie P; Browning MJ
Immunology; 1999 Dec; 98(4):541-50. PubMed ID: 10594686
[TBL] [Abstract][Full Text] [Related]
7. Antigen-presenting cells for unprimed T cells.
Sprent J; Schaefer M
Immunol Today; 1989 Jan; 10(1):17-23. PubMed ID: 2526637
[TBL] [Abstract][Full Text] [Related]
8. Playing hide and seek: Tumor cells in control of MHC class I antigen presentation.
Jongsma MLM; Neefjes J; Spaapen RM
Mol Immunol; 2021 Aug; 136():36-44. PubMed ID: 34082257
[TBL] [Abstract][Full Text] [Related]
9. [Molecular targets for development of cancer immunotherapy].
Kawakami Y
Nihon Rinsho; 2012 Nov; 70 Suppl 8():144-8. PubMed ID: 23513828
[No Abstract] [Full Text] [Related]
10. Using monoclonal antibodies to stimulate antitumor cellular immunity.
Durrant LG; Pudney VA; Spendlove I
Expert Rev Vaccines; 2011 Jul; 10(7):1093-106. PubMed ID: 21806402
[TBL] [Abstract][Full Text] [Related]
11. SV-BR-1-GM, a Clinically Effective GM-CSF-Secreting Breast Cancer Cell Line, Expresses an Immune Signature and Directly Activates CD4
Lacher MD; Bauer G; Fury B; Graeve S; Fledderman EL; Petrie TD; Coleal-Bergum DP; Hackett T; Perotti NH; Kong YY; Kwok WW; Wagner JP; Wiseman CL; Williams WV
Front Immunol; 2018; 9():776. PubMed ID: 29867922
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy of cancer by antisense inhibition of Ii protein, an immunoregulator of antigen selection by MHC class II molecules.
Xu M; Lu X; Kallinteris NL; Wang Y; Wu S; von Hofe E; Gulfo JV; Humphreys RE; Hillman GG
Curr Opin Mol Ther; 2004 Apr; 6(2):160-5. PubMed ID: 15195928
[TBL] [Abstract][Full Text] [Related]
13. Antigen cross-presentation and T-cell cross-priming in cancer immunology and immunotherapy.
Sánchez-Paulete AR; Teijeira A; Cueto FJ; Garasa S; Pérez-Gracia JL; Sánchez-Arráez A; Sancho D; Melero I
Ann Oncol; 2017 Dec; 28(suppl_12):xii44-xii55. PubMed ID: 28945841
[TBL] [Abstract][Full Text] [Related]
14. [Perspectives for tumour immunology: antigen-specific immunotherapy of malignant diseases].
Jäger E; Jäger D; Knuth A
Dtsch Med Wochenschr; 2001 Sep; 126(37):1011-6. PubMed ID: 11555776
[No Abstract] [Full Text] [Related]
15. Present Yourself! By MHC Class I and MHC Class II Molecules.
Rock KL; Reits E; Neefjes J
Trends Immunol; 2016 Nov; 37(11):724-737. PubMed ID: 27614798
[TBL] [Abstract][Full Text] [Related]
16. MHC class II restricted neoantigen: A promising target in tumor immunotherapy.
Sun Z; Chen F; Meng F; Wei J; Liu B
Cancer Lett; 2017 Apr; 392():17-25. PubMed ID: 28104443
[TBL] [Abstract][Full Text] [Related]
17. Using Antigen-Specific B Cells to Combine Antibody and T Cell-Based Cancer Immunotherapy.
Wennhold K; Thelen M; Schlößer HA; Haustein N; Reuter S; Garcia-Marquez M; Lechner A; Kobold S; Rataj F; Utermöhlen O; Chakupurakal G; Theurich S; Hallek M; Abken H; Shimabukuro-Vornhagen A; von Bergwelt-Baildon M
Cancer Immunol Res; 2017 Sep; 5(9):730-743. PubMed ID: 28778961
[TBL] [Abstract][Full Text] [Related]
18. Targeting tumours with genetically enhanced T lymphocytes.
Sadelain M; Rivière I; Brentjens R
Nat Rev Cancer; 2003 Jan; 3(1):35-45. PubMed ID: 12509765
[TBL] [Abstract][Full Text] [Related]
19. Turning tumor cells in situ into T-helper cell-stimulating, MHC class II tumor epitope-presenters: immuno-curing and immuno-consolidation.
Hillman GG; Kallinteris NL; Lu X; Wang Y; Wright JL; Li Y; Wu S; Forman JD; Gulfo JV; Humphreys RE; Xu M
Cancer Treat Rev; 2004 May; 30(3):281-90. PubMed ID: 15059651
[TBL] [Abstract][Full Text] [Related]
20. Cancer vaccines.
Greten TF; Jaffee EM
J Clin Oncol; 1999 Mar; 17(3):1047-60. PubMed ID: 10071300
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
